Miguel de Mulder Rougvie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6236584/publications.pdf

Version: 2024-02-01

32 papers	709 citations	516681 16 h-index	580810 25 g-index
34 all docs	34 docs citations	34 times ranked	1130 citing authors

#	Article	IF	Citations
1	Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression. PLoS Computational Biology, 2019, 15, e1006453.	3.2	99
2	Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain. Current HIV Research, 2008, 6, 327-334.	0.5	58
3	Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target. Viruses, 2020, 12, 726.	3.3	55
4	Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology, 2014, 11, 10.	2.0	43
5	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-NaÃ¯ve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. Journal of Clinical Microbiology, 2012, 50, 407-413.	3.9	41
6	MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection. PLoS Neglected Tropical Diseases, 2018, 12, e0006154.	3.0	38
7	High Drug Resistance Prevalence among Vertically HIV-Infected Patients Transferred from Pediatric Care to Adult Units in Spain. PLoS ONE, 2012, 7, e52155.	2.5	31
8	HIV-1 non-B subtypes: High transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Research, 2010, 85, 409-417.	4.1	29
9	Increase of Transmitted Drug Resistance among HIV-Infected Sub-Saharan Africans Residing in Spain in Contrast to the Native Population. PLoS ONE, 2011, 6, e26757.	2.5	29
10	Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers. Retrovirology, 2017, 14, 41.	2.0	22
11	Prevalence of Transmitted HIV-1 Drug Resistance Mutations in Children and Adolescents in SÃ£o Paulo, Brazil. Pediatric Infectious Disease Journal, 2012, 31, e255-e257.	2.0	21
12	Cutting Edge: An Antibody Recognizing Ancestral Endogenous Virus Glycoproteins Mediates Antibody-Dependent Cellular Cytotoxicity on HIV-1â€“Infected Cells. Journal of Immunology, 2014, 193, 1544-1548.	0.8	21
13	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naÃ¯ve HIV-infected patients (CoRIS). Antiviral Research, 2011, 89, 19-25.	4.1	20
14	Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2). Journal of Medical Virology, 2021, 93, 187-189.	5.0	18
15	Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 2362-2371.	3.0	17
16	Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005â€“2007). AIDS Research and Human Retroviruses, 2009, 25, 37-44.	1.1	16
17	Trends in Drug Resistance Prevalence in HIV-1â€“infected Children in Madrid. Pediatric Infectious Disease Journal, 2012, 31, e213-e221.	2.0	16
18	Transcriptomic analysis of human endogenous retroviruses in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21350-21351.	7.1	13

#	Article	IF	Citations
19	Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of Biomolecular Structure and Dynamics, 2022, 40, 7367-7380.	3.5	13
20	Description of HIV-1 Group M Molecular Epidemiology and Drug Resistance Prevalence in Equatorial Guinea from Migrants in Spain. PLoS ONE, 2013, 8, e64293.	2.5	12
21	Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. Frontiers in Oncology, 2020, 10, 553983.	2.8	11
22	Drug Resistance Prevalence in Human Immunodeficiency Virus Type 1 Infected Pediatric Populations in Honduras and El Salvador During 1989â€“2009. Pediatric Infectious Disease Journal, 2011, 30, e82-e87.	2.0	10
23	<scp>HIV</scp>â€1 drug resistance prevalence, drug susceptibility and variant characterization in the <scp>J</scp>acobi <scp>M</scp>edical <scp>C</scp>enter paediatric cohort, <scp>B</scp>ronx, <scp>NY</scp>, <scp>USA</scp>. HIV Medicine, 2014, 15, 135-143.	2.2	10
24	Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses. Clinical Microbiology and Infection, 2015, 21, 605.e1-605.e9.	6.0	10
25	IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight, 2017, 2, e85811.	5.0	10
26	The behavioral, cellular and immune mediators of HIV-1 acquisition: New insights from population genetics. Scientific Reports, 2020, 10, 3304.	3.3	8
27	Expression of Retroelements in Cervical Cancer and Their Interplay with HPV Infection and Host Gene Expression. Cancers, 2021, 13, 3513.	3.7	7
28	Hallmarks of Retroelement Expression in T-Cells Treated With HDAC Inhibitors. Frontiers in Virology, 2021, 1, .	1.4	5
29	Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2019, 35, 108-111.	1.1	3
30	Restriction of HIV-1 Infection in Sickle Cell Trait. Blood Advances, 2021, 5, 4922-4934.	5.2	2
31	Restriction Factor Expression in Vertically Infected Children Living With HIV-1. Pediatric Infectious Disease Journal, 2021, 40, 144-146.	2.0	0
32	Restriction of HIV-1 Infection in Sickle Cell Disease and Trait. Blood, 2018, 132, 2337-2337.	1.4	0